Somatostatin 14 - RELIEF THERAPEUTICS Holding

Drug Profile

Somatostatin 14 - RELIEF THERAPEUTICS Holding

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Antineoplastics; Cyclic peptides; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Hepatitis B

Most Recent Events

  • 20 Sep 2016 Somatostatin 14 is available for licensing as of 20 Sep 2016.
  • 20 Sep 2016 Preclinical trials in Hepatitis B in Switzerland (unspecified route)
  • 08 Jan 2014 mondoBIOTECH has patent protection for somatostatin 14 in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top